Medicinova (MNOV) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Medicinova (MNOV) has outperformed Rafael (RFL) over the past year, gaining 28.8% versus a gain of 9.6%. Over five years, MNOV leads with a -57.9% price change compared with -95.1% for RFL. Rafael is the larger company by market cap ($77.0 million vs $75.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | RFL |
|---|---|---|
| Share price | $1.54 | $1.48 |
| Market cap | $75.80M | $76.96M |
| 1-day change | -4.35% | 0.00% |
| YTD return | +22.90% | +25.42% |
| 1-year return | +28.80% | +9.63% |
| 5-year return | -57.85% | -95.09% |
| EPS (TTM) | $-0.21 | $-0.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $3.96 |
| 52-week low | $1.17 | $1.12 |
| Distance from 52-week high | -60.51% | -62.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +435.71% | — |
| Average volume | 321.31K | 159.82K |
| Shares outstanding | 49.22M | 51.21M |
| Employees | 6 | 21 |
| Sector | Healthcare | Real Estate |
| Industry | Biotechnology | Real Estate Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed RFL by 19.2 percentage points over the past year.
- The two companies sit in different sectors: Medicinova in Healthcare and Rafael in Real Estate.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Healthcare · Biotechnology · 6 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Real Estate · Real Estate Services · 21 employees
MNOV vs RFL FAQ
Which is bigger, Medicinova or Rafael?
Rafael (RFL) is larger, with a market capitalization of $76.96M compared with $75.80M for Medicinova (MNOV).
Which stock has performed better over the past year, MNOV or RFL?
MNOV returned +28.80% over the past 12 months, compared with +9.63% for RFL (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Rafael in the same industry?
No. Medicinova is in the Healthcare sector, while Rafael is in Real Estate.